GAA Chaperone Therapy for Pompe Disease CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Pompe disease, such as enzyme-replacement therapy (ERT) and gene therapy, face limitations in effectively treating central nervous system (CNS) dysfunctions due to poor biodistribution and high immunogenicity, particularly in increasing the uptake of acid-alpha glucosidase (GAA) in nervous system tissues, leading to inadequate correction of glycogen accumulation and respiratory impairments.
Innovation Solution
A combination of pharmacological chaperones like 1-deoxynojirimycin (DNJ) and ambroxol (ABX) is used in conjunction with therapeutic acid-alpha glucosidase polypeptides or nucleic acid molecules to enhance the stability and tissue uptake of GAA, improving its delivery and efficacy in treating CNS dysfunctions and respiratory neuromuscular impairments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme-replacement therapy (ERT) with recombinant human GAA is administered, then GAA activity is restored in muscle tissues, but the therapy fails to effectively treat CNS dysfunctions due to poor blood-brain barrier penetration and high immunogenicity
Solution Approach 1:
The patent uses pharmacological chaperones (DNJ and ABX) as intermediary molecules that facilitate the transport of GAA across the blood-brain barrier. These chaperones bind to GAA, forming a complex that can penetrate the BBB and deliver the enzyme to CNS tissues, thereby resolving the penetration issue without requiring modification of the GAA protein itself
Solution Approach 2:
The patent modifies the physical-chemical parameters of GAA by forming complexes with pharmacological chaperones. This changes the biodistribution profile and immunogenicity characteristics of GAA, enabling it to cross the blood-brain barrier and reducing immune recognition, thus improving CNS delivery efficacy
2Duration of action of moving object
If frequent infusions of recombinant hGAA are administered to maintain therapeutic levels, then GAA activity is sustained in muscle tissues, but the development of inhibitor antibodies reduces treatment efficacy over time
Solution Approach 1:
Pharmacological chaperones serve as protective intermediaries that shield GAA from immune system recognition. By forming stable complexes with GAA, these chaperones prevent antibody binding and immune clearance, allowing sustained therapeutic levels without the development of neutralizing antibodies that would otherwise limit treatment duration
3Stability of the object's composition
If pharmacological chaperones alone are administered, then GAA stability is enhanced, but GAA uptake in nervous system tissues remains insufficient without combination therapy
Solution Approach 1:
The patent combines two pharmacological chaperones (DNJ and ABX) with therapeutic GAA in a triple-therapy regimen. This merging of multiple agents creates synergistic effects where DNJ and ABX collectively enhance both the stability and the nervous system tissue uptake of GAA, overcoming the limitations of using either chaperone alone
4Duration of action of stationary object
If gene therapy approaches are used to deliver GAA, then sustained GAA production is achieved in some tissues, but glycogen accumulation is only partially rescued in the central nervous system
Solution Approach 1:
The patent introduces pharmacological chaperones as intermediary agents that work in conjunction with gene therapy. These chaperones enhance the stability and neuronal uptake of the GAA protein produced by gene therapy, ensuring that the sustained GAA production translates into effective glycogen clearance in CNS tissues rather than just protein expression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of DNJ and ABX significantly increases circulating and tissue levels of GAA, reducing glycogen accumulation and improving respiratory function in both animal models and patients with Pompe disease, thereby addressing the limitations of existing therapies.
Implementation Method 1
A combination of pharmacological chaperones like 1-deoxynojirimycin (DNJ) and ambroxol (ABX) is used in conjunction with therapeutic acid-alpha glucosidase polypeptides to enhance the stability and tissue uptake of GAA
Implementation Method 2
administration of a pharmacological chaperone for facilitating the folding and enhancing the stability of GAA
Implementation Method 3
GAA is an exo-1,4 and 1,6-α-glucosidase that hydrolyzes glycogen to glucose in the lysosome
Implementation Method 4
acid alpha-glucosidase (GAA). GAA is an exo-1,4 and 1,6-α-glucosidase that hydrolyzes glycogen to glucose in the lysosome
Implementation Method 5
The combination of DNJ and ABX significantly increases circulating and tissue levels of GAA, reducing glycogen accumulation and improving respiratory function
Data Source
AI summary
The invention relates to a kit of parts comprising (i) pharmacological chaperones or a pharmaceutically acceptable salt thereof and (ii) a therapeutic acid-alpha glucosidase (GAA) polypeptide or a nucleic acid molecule encoding a therapeutic GAA polypeptide, wherein said pharmacological chaperones are 1-deoxynojirimycin (DNJ) or a derivative thereof and ambroxol (ABX) or a derivative thereof.